Upadacitinib Hemihydrate is a potent Janus kinase (JAK) inhibitor and a small molecule tyrosine kinase inhibitor used to treat moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, and plaque… Read more
Upadacitinib Hemihydrate is a potent Janus kinase (JAK) inhibitor and a small molecule tyrosine kinase inhibitor used to treat moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis by modulating the JAK-STAT signaling pathway. This collection includes reference standards of the active pharmaceutical ingredient, along with related pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical and analytical laboratories require these high-quality materials for comprehensive impurity profiling and rigorous quality control processes. Scientists utilize these reference standards for bioanalytical method validation and to ensure accurate quantification during stability testing and routine drug analysis. By providing precise chemical benchmarks for the detection and characterization of potential degradation products or metabolic byproducts, these compounds are essential for maintaining regulatory compliance and ensuring the therapeutic efficacy and safety of the final drug product.